Imagenebio, Inc.

ImageneBio Announces $30 Million Private Placement

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team